Aktie A3EEKJ TISSUE REPAIR LTD
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Tissue Repair Ltd

Aktien

A3EEKJ

AU0000180887

TRP

Markt geschlossen - Australian S.E.
Andere Börsenplätze
 06:53:18 26.04.2024 		% 5 Tage % 1. Jan.
0.23 AUD 0.00% Intraday Chart für Tissue Repair Ltd -4.17% +4.55%
29.02. Tissue Repair Limited gibt den Wechsel des Company Secretary bekannt CI
28.02. Tissue Repair Ltd berichtet über die Ergebnisse für das am 31. Dezember 2023 endende Halbjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Tissue Repair Limited Announces Change of Company Secretary
Tissue Repair Ltd Reports Earnings Results for the Half Year Ended December 31, 2023
Tissue Repair Secures Third US Patent for Glucoprime Compound
17,604,240 Options of Tissue Repair Ltd are subject to a Lock-Up Agreement Ending on 18-NOV-2023.
13,684,488 Ordinary Shares of Tissue Repair Ltd are subject to a Lock-Up Agreement Ending on 18-NOV-2023.
Tissue Repair Ltd Reports Earnings Results for the Full Year Ended June 30, 2023
Tissue Repair Limited Announces Company Secretary Changes
Tissue Repair Secures US FDA Clearance for Phase Three Leg Ulcer Trial
Tissue Repair Ltd Appoints Michael Silberberg as Director
Tissue Repair Ltd Announces Board Resignations
Tissue Repair Ltd Reports Earnings Results for the Half Year Ended December 31, 2022
Tissue Repair to Test TR-987 Drug in 2023
Tissue Repair Ltd Announces Change of Company Secretary
Tissue Repair Limited Announces That It Has Received Responses to the Matters Raised in the Type C Meeting That the Company Submitted to the FDA on June 29, 2022
Tissue Repair Secures Second US Patent for Use of Active Ingredient in Skin Conditions
Tissue Repair Limited to Enter a Phase 3 Program in Venous Leg Ulcers
BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
3,770,440 Ordinary Shares of Tissue Repair Ltd are subject to a Lock-Up Agreement Ending on 30-APR-2022.
Australian Shares Fall Amid Global Selloff as Russia Continues Assault on Ukraine
Tissue Repair Secures US Patent Approval for Wound Drug; Shares Sink 8%
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3EEKJ Aktie
  4. Nachrichten Tissue Repair Ltd
  5. Andere Sprachen